News

Quest Diagnostic has posted an increase in the net revenues to $1.9 billion for the second quarter of 2009, as compared to $1.8 billion for the same period

Pfizer has declared the results for a 96-week follow up data from the MERITES analysis, for HIV patients taking Celsentri/Selzentry (maraviroc) in combination with Combivir (zidovudine/lamivudine). The results

The FDA has approved Novartis’ Tekturna HCT (aliskiren and hydrochlorothiazide) tablets, as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure

BioAlliance has signed a co-promotion agreement with Lundbeck for Seroplex antidepressant. Reportedly, the company would co-promote Seroplex to its core healthcare partners, as part of a comprehensive approach

Stem Cell Therapeutics (SCT) has received a No Objection Letter (NOL) from the Drug Controller General of India (DCGI), to initiate the phase IIb acute ischemic stroke trial.

Ranbaxy has received final approval in Canada to manufacture and market Ran-Simvastatin 5mg, 10mg, 20mg, 40mg and 80mg tablets (Simvastatin), from Health Canada, Therapeutic Products Directorate (TPD). Ran-Simvastatin

Poniard has reported the results of phase 1 cardiac safety study of picoplatin, a new generation platinum-based chemotherapy agent. The study evaluated the cardiac safety of picoplatin by

Dr Reddy’s Laboratories has announced its unaudited financial results for the first quarter ended June, 2009. The company has reported an overall revenues of $381 million in Q1

GlaxoSmithKline (GSK) and Enigma Diagnostics have signed worldwide agreements to develop and supply the first point of care diagnostic influenza tests. It is to identify specific influenza virus